-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: NXP-900 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Ovarian Cancer Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Cervical Cancer Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Colon Cancer Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Pancreatic Cancer Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Solid Tumor Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Medulloblastoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Medulloblastoma Drug Details: NXP-900 is under development for the treatment of medulloblastoma, triple-negative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Non-Small Cell Lung Cancer Drug Details: NXP-900 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Skin Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Skin Cancer Drug Details: NXP-900 is under development for the treatment of medulloblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: NXP-900 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Triple-Negative Breast Cancer (TNBC) Drug Details: NXP-900 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Esophageal Squamous Cell Carcinoma (ESCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details: NXP-900 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRAX-628 in Epilepsy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRAX-628 in Epilepsy Drug Details: PRAX-628 is under development for the treatment of focal onset...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TED-N in Paralysis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Paralysis Drug Details:Stem cell therapy is under development for the treatment of sub-acute spinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-800 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NXP-800 in Solid Tumor Drug Details:NXP-800 is under development for the treatment of solid tumors, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-800 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NXP-800 in Endometrial Cancer Drug Details:NXP-800 is under development for the treatment of solid tumors, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – V-306 in Respiratory Syncytial Virus (RSV) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.V-306 in Respiratory Syncytial Virus (RSV) InfectionsDrug Details:V-306 is under development for the prevention of respiratory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTD-1801 in Liver Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTD-1801 in Liver Fibrosis Drug Details: HTD-1801 (berberine ursodeoxycholate) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-900 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-900 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: NXP-900 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXP-800 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXP-800 in Ovarian Cancer Drug Details: NXP-800 is under development for the treatment of solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.